Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcadia Biosciences (RKDA) Change in Receivables (2016 - 2025)

Arcadia Biosciences filings provide 12 years of Change in Receivables readings, the most recent being -$406000.0 for Q4 2025.

  • On a quarterly basis, Change in Receivables fell 228.08% to -$406000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was -$165000.0, a 121.65% decrease, with the full-year FY2025 number at -$165000.0, down 121.65% from a year prior.
  • Change in Receivables hit -$406000.0 in Q4 2025 for Arcadia Biosciences, down from -$176000.0 in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $1.4 million in Q1 2022 to a low of -$1.1 million in Q4 2022.
  • Median Change in Receivables over the past 5 years was $29000.0 (2021), compared with a mean of -$6950.0.
  • Biggest five-year swings in Change in Receivables: tumbled 15985.71% in 2022 and later soared 1357.14% in 2024.
  • Arcadia Biosciences' Change in Receivables stood at -$7000.0 in 2021, then tumbled by 15985.71% to -$1.1 million in 2022, then surged by 105.77% to $65000.0 in 2023, then skyrocketed by 387.69% to $317000.0 in 2024, then plummeted by 228.08% to -$406000.0 in 2025.
  • The last three reported values for Change in Receivables were -$406000.0 (Q4 2025), -$176000.0 (Q3 2025), and $224000.0 (Q2 2025) per Business Quant data.